{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T18:18:42Z","timestamp":1790965122513,"version":"4.1.0"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,11,12]],"date-time":"2024-11-12T00:00:00Z","timestamp":1731369600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,11,12]],"date-time":"2024-11-12T00:00:00Z","timestamp":1731369600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100000900","name":"California Institute for Regenerative Medicine","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000900","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"DOI":"10.1038\/s41467-024-54077-5","type":"journal-article","created":{"date-parts":[[2024,11,12]],"date-time":"2024-11-12T10:31:13Z","timestamp":1731407473000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":37,"title":["A framework for N-of-1 trials of individualized gene-targeted therapies for genetic diseases"],"prefix":"10.1038","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4785-7795","authenticated-orcid":false,"given":"Olivia","family":"Kim-McManus","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0889-9220","authenticated-orcid":false,"given":"Joseph G.","family":"Gleeson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurence","family":"Mignon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amena","family":"Smith Fine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Winston","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-3052-289X","authenticated-orcid":false,"given":"Nicole","family":"Nolen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott","family":"Demarest","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7099-1522","authenticated-orcid":false,"given":"Elizabeth","family":"Berry-Kravis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9351-7054","authenticated-orcid":false,"given":"Richard","family":"Finkel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefanie","family":"Leonard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samuel","family":"Finlayson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erika","family":"Augustine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5869-0716","authenticated-orcid":false,"given":"Gholson J.","family":"Lyon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca","family":"Schule","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2988-7701","authenticated-orcid":false,"given":"Timothy","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,11,12]]},"reference":[{"key":"54077_CR1","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1038\/s42003-024-06121-9","volume":"7","author":"V Baylot","year":"2024","unstructured":"Baylot, V., Le, T. K., Ta\u00efeb, D., Rocchi, P. & Colleaux, L. Between hope and reality: treatment of genetic diseases through nucleic acid-based drugs. Commun. Biol. 7, 489 (2024).","journal-title":"Commun. Biol."},{"key":"54077_CR2","doi-asserted-by":"publisher","first-page":"1678","DOI":"10.1056\/NEJMe1911295","volume":"381","author":"J Woodcock","year":"2019","unstructured":"Woodcock, J. & Marks, P. Drug regulation in the era of individualized therapies. N. Engl. J. Med. 381, 1678\u20131680 (2019).","journal-title":"N. Engl. J. Med."},{"key":"54077_CR3","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1038\/s41434-020-0143-y","volume":"28","author":"P Marks","year":"2021","unstructured":"Marks, P. & Witten, C. Toward a new framework for the development of individualized therapies. Gene Ther. 28, 615\u2013617 (2021).","journal-title":"Gene Ther."},{"key":"54077_CR4","doi-asserted-by":"publisher","first-page":"1644","DOI":"10.1056\/NEJMoa1813279","volume":"381","author":"J Kim","year":"2019","unstructured":"Kim, J. et al. Patient-customized oligonucleotide therapy for a rare genetic disease. N. Engl. J. Med. 381, 1644\u20131652 (2019).","journal-title":"N. Engl. J. Med."},{"key":"54077_CR5","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1038\/s41591-021-01557-6","volume":"28","author":"H Tran","year":"2022","unstructured":"Tran, H. et al. Suppression of mutant C9orf72 expression by a potent mixed backbone antisense oligonucleotide. Nat. Med. 28, 117\u2013124 (2022).","journal-title":"Nat. Med."},{"key":"54077_CR6","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1038\/s41591-021-01615-z","volume":"28","author":"VA Korobeynikov","year":"2022","unstructured":"Korobeynikov, V. A., Lyashchenko, A. K., Blanco-Redondo, B., Jafar-Nejad, P. & Shneider, N. A. Antisense oligonucleotide silencing of FUS expression as a therapeutic approach in amyotrophic lateral sclerosis. Nat. Med. 28, 104\u2013116 (2022).","journal-title":"Nat. Med."},{"key":"54077_CR7","doi-asserted-by":"publisher","first-page":"828","DOI":"10.1038\/s41586-023-06277-0","volume":"619","author":"J Kim","year":"2023","unstructured":"Kim, J. et al. A framework for individualized splice-switching oligonucleotide therapy. Nature 619, 828\u2013836 (2023).","journal-title":"Nature"},{"key":"54077_CR8","unstructured":"Fda, U. Nonclinical testing of individualized antisense oligonucleotide drug products for severely debilitating or life-threatening diseases. Draft Guidance. pdf. (2021)."},{"key":"54077_CR9","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1056\/NEJM198604033141406","volume":"314","author":"G Guyatt","year":"1986","unstructured":"Guyatt, G. et al. Determining optimal therapy\u2013randomized trials in individual patients. N. Engl. J. Med. 314, 889\u2013892 (1986).","journal-title":"N. Engl. J. Med."},{"key":"54077_CR10","unstructured":"Center for Drug Evaluation & Research. FDA Patient-Focused Drug Development Guidance Series for Enhancing the Incorporation of the Patient\u2019s Voice in Medical Product Development and Regulatory Decision Making. U.S. Food and Drug Administration https:\/\/www.fda.gov\/drugs\/development-approval-process-drugs\/fda-patient-focused-drug-development-guidance-series-enhancing-incorporation-patients-voice-medical (2024)."},{"key":"54077_CR11","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1016\/0197-2456(89)90005-6","volume":"10","author":"R Jaeschke","year":"1989","unstructured":"Jaeschke, R., Singer, J. & Guyatt, G. H. Measurement of health status. Ascertaining the minimal clinically important difference. Control. Clin. Trials 10, 407\u2013415 (1989).","journal-title":"Control. Clin. Trials"},{"key":"54077_CR12","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1016\/j.spinee.2007.01.008","volume":"7","author":"AG Copay","year":"2007","unstructured":"Copay, A. G., Subach, B. R., Glassman, S. D., Polly, D. W. Jr & Schuler, T. C. Understanding the minimum clinically important difference: a review of concepts and methods. Spine J. 7, 541\u2013546 (2007).","journal-title":"Spine J."},{"key":"54077_CR13","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1002\/mus.23905","volume":"48","author":"CM McDonald","year":"2013","unstructured":"McDonald, C. M. et al. The 6-minute walk test and other clinical endpoints in Duchenne muscular dystrophy: reliability, concurrent validity, and minimal clinically important differences from a multicenter study. Muscle Nerve 48, 357\u2013368 (2013).","journal-title":"Muscle Nerve"},{"key":"54077_CR14","unstructured":"Center for Drug Evaluation & Research. Patient-focused drug development: Methods to identify what is important to patients. U.S. Food and Drug Administration https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/patient-focused-drug-development-methods-identify-what-important-patients (2022)."},{"key":"54077_CR15","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1007\/s12687-020-00500-5","volume":"12","author":"M Vink\u0161el","year":"2021","unstructured":"Vink\u0161el, M., Writzl, K., Maver, A. & Peterlin, B. Improving diagnostics of rare genetic diseases with NGS approaches. J. Community Genet. 12, 247\u2013256 (2021).","journal-title":"J. Community Genet."},{"key":"54077_CR16","doi-asserted-by":"crossref","unstructured":"Bax, B. E. Biomarkers in rare diseases 2.0. Int. J. Mol. Sci. 23, 4582 (2022).","DOI":"10.3390\/ijms23094582"},{"key":"54077_CR17","doi-asserted-by":"publisher","first-page":"S59","DOI":"10.1111\/epi.14935","volume":"60","author":"M Wolff","year":"2019","unstructured":"Wolff, M., Brunklaus, A. & Zuberi, S. M. Phenotypic spectrum and genetics of SCN2A-related disorders, treatment options, and outcomes in epilepsy and beyond. Epilepsia 60, S59\u2013S67 (2019).","journal-title":"Epilepsia"},{"key":"54077_CR18","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-021-01805-5","volume":"16","author":"PK Tandon","year":"2021","unstructured":"Tandon, P. K. & Kakkis, E. D. The multi-domain responder index: a novel analysis tool to capture a broader assessment of clinical benefit in heterogeneous complex rare diseases. Orphanet J. Rare Dis. 16, 183 (2021).","journal-title":"Orphanet J. Rare Dis."},{"key":"54077_CR19","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1186\/s41687-021-00336-8","volume":"5","author":"WR Lenderking","year":"2021","unstructured":"Lenderking, W. R. et al. Measuring health-related quality of life in patients with rare disease. J. Patient Rep. Outcomes 5, 61 (2021).","journal-title":"J. Patient Rep. Outcomes"},{"key":"54077_CR20","doi-asserted-by":"publisher","first-page":"334","DOI":"10.4103\/aian.aian_207_23","volume":"26","author":"B Mishra","year":"2023","unstructured":"Mishra, B. et al. Minimal clinically important difference (MCID) in patient-reported outcome measures for neurological conditions: review of concept and methods. Ann. Indian Acad. Neurol. 26, 334\u2013343 (2023).","journal-title":"Ann. Indian Acad. Neurol."},{"key":"54077_CR21","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.1158\/2159-8290.CD-22-1377","volume":"13","author":"MA Gouda","year":"2023","unstructured":"Gouda, M. A., Buschhorn, L., Schneeweiss, A., Wahida, A. & Subbiah, V. N-of-1 trials in cancer drug development. Cancer Discov. 13, 1301\u20131309 (2023).","journal-title":"Cancer Discov."},{"key":"54077_CR22","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1038\/nature15819","volume":"526","author":"AV Biankin","year":"2015","unstructured":"Biankin, A. V., Piantadosi, S. & Hollingsworth, S. J. Patient-centric trials for therapeutic development in precision oncology. Nature 526, 361\u2013370 (2015).","journal-title":"Nature"},{"key":"54077_CR23","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.jclinepi.2016.03.026","volume":"76","author":"S Punja","year":"2016","unstructured":"Punja, S. et al. N-of-1 trials can be aggregated to generate group mean treatment effects: a systematic review and meta-analysis. J. Clin. Epidemiol. 76, 65\u201375 (2016).","journal-title":"J. Clin. Epidemiol."},{"key":"54077_CR24","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1002\/ajmg.c.32031","volume":"193","author":"J Lekstrom-Himes","year":"2023","unstructured":"Lekstrom-Himes, J. et al. Moving away from one disease at a time: Screening, trial design, and regulatory implications of novel platform technologies. Am. J. Med. Genet. C Semin. Med. Genet. 193, 30\u201343 (2023).","journal-title":"Am. J. Med. Genet. C Semin. Med. Genet."},{"key":"54077_CR25","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1002\/ajmg.c.32028","volume":"193","author":"J Lekstrom-Himes","year":"2023","unstructured":"Lekstrom-Himes, J. et al. Data sharing to advance gene-targeted therapies in rare diseases. Am. J. Med. Genet. C Semin. Med. Genet. 193, 87\u201398 (2023).","journal-title":"Am. J. Med. Genet. C Semin. Med. Genet."},{"key":"54077_CR26","doi-asserted-by":"publisher","first-page":"1142","DOI":"10.1177\/0883073813495959","volume":"28","author":"EF Augustine","year":"2013","unstructured":"Augustine, E. F., Adams, H. R. & Mink, J. W. Clinical trials in rare disease: challenges and opportunities. J. Child Neurol. 28, 1142\u20131150 (2013).","journal-title":"J. Child Neurol."},{"key":"54077_CR27","doi-asserted-by":"publisher","unstructured":"Pian, J. M. Y. et al. How to pay for individualized genetic medicines. Nat. Med. https:\/\/doi.org\/10.1038\/s41591-024-03071-x (2024).","DOI":"10.1038\/s41591-024-03071-x"}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-024-54077-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-024-54077-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-024-54077-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,12]],"date-time":"2024-11-12T11:02:07Z","timestamp":1731409327000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-024-54077-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,12]]},"references-count":27,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["54077"],"URL":"https:\/\/doi.org\/10.1038\/s41467-024-54077-5","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,12]]},"assertion":[{"value":"15 March 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 November 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 November 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Joseph Gleeson serves as a consultant for Ionis Pharmaceuticals, Neurocrine Pharmaceuticals, and the n-Lorem Foundation. Winston Yan is a founder, employee, and shareholder of Arbor Biotechnologies, and serves as President and Board Member of the N=1 Collaborative. Timothy Yu has received research support from EveryONE Medicines, and volunteer Board Member for the N=1 Collaborative, the Oligonucleotide Therapeutics Society, and the Society for RNA Therapeutics, and a volunteer advisor to several rare disease foundations. The remaining authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"9802"}}